The findings suggest a potential role for the drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) in the treatment of alcohol-use disorder. Compared to participants taking an active comparator drug, those taking GLP-1 receptor agonists had a lower risk of alcohol-related admission to hospital during all four trials. In the MAUD trials, the active comparators were drugs for alcohol-use disorder including acamprosate, disulfiram and naltrexone. “These findings may suggest a potential role for GLP-1 receptor agonists in the context of alcohol-use disorder.” Reference:Rodriguez PJ, Lusk JB, Mehta HB, et alAssociation between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation studyBMJ Open 2026;16:e109259.